Are Analysts Bearish Circassia Pharmaceuticals Plc (LON:CIR) After Last Week?

April 17, 2018 - By Michael Collier

Circassia Pharmaceuticals Plc (LON:CIR) LogoInvestors sentiment increased to 1.02 in Q4 2017. Its up 0.02, from 1 in 2017Q3. It is positive, as 7 investors sold Circassia Pharmaceuticals Plc shares while 37 reduced holdings. 12 funds opened positions while 33 raised stakes. 16.91 million shares or 4.21% more from 16.23 million shares in 2017Q3 were reported.
Metropolitan Life Insur invested in 0% or 5,544 shares. Utd Automobile Association accumulated 137,946 shares. Thrivent For Lutherans, a Minnesota-based fund reported 59,989 shares. Glenmede Tru Na accumulated 84 shares. Teton Advisors invested in 183,600 shares. Boothbay Fund Mgmt Ltd Liability Corporation stated it has 5,343 shares. California State Teachers Retirement System holds 0% in Circassia Pharmaceuticals Plc (LON:CIR) or 26,044 shares. Texas Permanent School Fund stated it has 0.01% in Circassia Pharmaceuticals Plc (LON:CIR). Wellington Management Group Llp holds 1.33M shares or 0.01% of its portfolio. 191,504 are held by Bancshares Of New York Mellon Corporation. Assetmark Inc invested in 6 shares. Deutsche Bancshares Ag stated it has 0% in Circassia Pharmaceuticals Plc (LON:CIR). Royal Bank Of Canada reported 404 shares or 0% of all its holdings. Huntington Bancorp reported 200 shares stake. Teacher Retirement Sys Of Texas holds 0% or 4,813 shares.

Circassia Pharmaceuticals Plc (LON:CIR) Ratings Coverage

Among 2 analysts covering Circassia Pharmaceuticals Plc (LON:CIR), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Circassia Pharmaceuticals Plc had 6 analyst reports since October 31, 2017 according to SRatingsIntel. As per Thursday, February 1, the company rating was maintained by Peel Hunt. Numis Securities maintained Circassia Pharmaceuticals Plc (LON:CIR) on Monday, December 4 with “Buy” rating. The firm earned “Hold” rating on Wednesday, April 4 by Peel Hunt. As per Tuesday, October 31, the company rating was maintained by Peel Hunt. Peel Hunt maintained it with “Hold” rating and GBX 130 target in Thursday, January 4 report. The firm has “Hold” rating given on Thursday, March 1 by Peel Hunt. Below is a list of Circassia Pharmaceuticals Plc (LON:CIR) latest ratings and price target changes.

04/04/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 Maintain
01/03/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
01/02/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/01/2018 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain
04/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 180.00 New Target: GBX 180.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Hold Old Target: GBX 130.00 New Target: GBX 130.00 Maintain

The stock decreased 0.11% or GBX 0.1 during the last trading session, reaching GBX 91.9. About 2,678 shares traded. Circassia Pharmaceuticals Plc (LON:CIR) has 0.00% since April 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Circassia Pharmaceuticals plc, a specialty biopharmaceutical company, focuses on the development and commercialization of products for the treatment of asthma and chronic obstructive pulmonary disease . The company has market cap of 306.46 million GBP. It markets novel NIOX asthma management products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners internationally. It currently has negative earnings. The companyÂ’s asthma products comprise Fliveo that targets substitution of Flixotide, which has approved in the United Kingdom, as well as developing Seriveo that targets direct substitution of Seretide.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: